Timor-Leste Reaches WHO Trachoma Elimination Milestone

Timor-Leste has become the 33rd country to receive World Health Organization validation for eliminating trachoma as a public health problem. The September 3 decision also closes the final suspected gap in WHO’s South-East Asia Region, where no country now needs trachoma-specific public-health intervention.

The wording matters. WHO validation does not mean the bacterium that causes trachoma can never appear again, or that every eye-care need has disappeared. It means Timor-Leste has met internationally defined prevalence thresholds and shown that its health system can find and manage future cases. Continued surveillance and treatment remain part of the achievement.

What WHO validated in Timor-Leste

According to WHO’s validation announcement, the decision followed years of field investigation and national evidence gathering. Investigations between 2015 and 2017 included examinations of children on Atauro Island, screening at eye clinics around the country and targeted house-to-house searches. Those efforts found no trachoma.

Timor-Leste later added a larger layer of evidence. A 2025 survey analyzed 4,949 samples from children aged one to five across all 13 municipalities. WHO said the testing found no transmission at a level that would require a trachoma-specific public-health response.

The organization also assessed whether the country could detect, investigate and manage cases after validation. Timor-Leste plans to fold trachoma monitoring into its existing disease and neglected-tropical-disease surveillance systems. Eye-care services, including surgery for trichiasis—the painful stage in which eyelashes turn inward—remain available through the National Eye Centre in Dili and municipal outreach.

Elimination is a measurable public-health standard

WHO’s trachoma fact sheet sets three elements for validation. In formerly endemic districts, active trachoma among children aged one to nine must remain below 5% for at least two years without continuing mass antibiotic treatment. Cases of trichiasis unknown to the health system must be below 0.2% among people aged 15 and older. The country must also have a funded system capable of finding and managing new trichiasis cases.

Those criteria explain why “eliminated as a public health problem” is more precise than saying the disease has been eradicated. Eradication would mean permanent worldwide reduction to zero. Validation instead recognizes that the disease is no longer occurring at levels that demand a dedicated public-health programme, while normal clinical care and surveillance continue.

Why trachoma remains a serious global issue

Trachoma is an eye disease caused by infection with Chlamydia trachomatis. It spreads through contact with eye or nasal discharge, including through hands, clothing, bedding, contaminated surfaces and some flies. Repeated infections can scar the inner eyelid. Over time, that scarring may turn the eyelashes inward so they scrape the cornea, causing pain, visual impairment and potentially irreversible blindness.

The disease is closely associated with poverty, crowding and inadequate access to clean water, sanitation and health care. WHO estimates that about 92 million people were living in trachoma-endemic areas as of March 2026, while roughly 1.9 million people were blind or visually impaired because of the disease. Women can face a greater lifetime burden because of more frequent close contact with young children, who are often the main reservoir of infection in endemic communities.

Global programmes use the WHO-recommended SAFE strategy: surgery for advanced trichiasis, antibiotics to clear infection, facial cleanliness and environmental improvements such as better water and sanitation. In 2025, WHO member states reported 98,829 corrective surgeries and antibiotic treatment for 47.4 million people in endemic communities.

A regional milestone built on national evidence

Timor-Leste was the last country in WHO’s South-East Asia Region where endemic trachoma was suspected. It is the region’s fourth country to complete the validation process; other member states either achieved validation earlier or had no history suggesting that validation was required. The result means trachoma is no longer considered a public-health problem anywhere in the region.

WHO credits the Timor-Leste Ministry of Health, health workers, communities and a group of eye-health and research partners for producing the evidence behind the decision. Those partners included the Royal Australasian College of Surgeons, the Fred Hollows Foundation, Menzies School of Health Research, the London School of Hygiene & Tropical Medicine, the Kirby Institute, Lions Clubs International Foundation and the International Agency for the Prevention of Blindness.

The milestone adds Timor-Leste to a wider global effort. As of September 2026, WHO counted 64 countries that had eliminated at least one neglected tropical disease. Timor-Leste is the 33rd country validated for eliminating trachoma as a public-health problem.

What happens after validation

The next phase is about protecting the gains. Health workers still need to recognize eye disease, patients still need access to surgery and other care, and public-health teams must be able to investigate any concerning cluster. Improvements in water, sanitation and hygiene serve a wider purpose too, reducing risks well beyond trachoma.

WHO’s global target is elimination of trachoma as a public-health problem worldwide by 2030. Timor-Leste’s experience shows that countries without obvious ongoing transmission may still need patient screening, targeted searches and population-level laboratory evidence before uncertainty can be closed responsibly.

For readers following verified health developments, more coverage is available in our News section. The essential point in this case is both hopeful and carefully bounded: Timor-Leste has met WHO’s public-health elimination standard, while surveillance and eye care continue.